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Abstract 
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that 
affects multiple organ systems within the female body, hallmarked by 
infertility, the possibility of androgen excess, and the possibility of 
ovulatory dysfunction. Along with a myriad of physiological symptoms, 
PCOS is also associated with many psychological issues, including an 
increased incidence of depression, anxiety, and lower reported quality of 
life among women diagnosed with PCOS. The need for treatment 
directed to attenuate any psychological implications of the syndrome has 
become increasingly important are of research. While some researchers 
have focused on PCOS in a psychosocial perspective, including analysis 
on depression, anxiety, and quality of life, more research is needed on 
how women with PCOS experience stress. This study examined how 16 
women with PCOS physiologically responded to a brief stressor, the 
Social Competence Interview (SCI), as compared to a healthy control 
population (n=64). Saliva samples were collected at 5 time points (S0-
S4) before, during, and after the interview to measure cortisol reactivity 
to the stressor. Further, the participants were asked to fill out 
questionnaires to gather information about their perceived stress, their 
psychiatric symptoms, and their physiological health. Results indicated 
that women with PCOS reported significantly more somatic complaints 
than healthy controls. Women with PCOS also had a higher baseline 
cortisol level than healthy controls. Future research should examine 
other psychological and physiological factors that could contribute to the 
experience of stress in women with PCOS.
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Executive Summary 
My capstone project examines how polycystic ovary syndrome (PCOS) 
affects the health and well-being of women diagnosed with the syndrome. 
Further, my project examines how women with polycystic ovary syndrome 
respond to a brief stressor, ultimately aiming to understand how women with 
PCOS experience stress. 
Polycystic ovary syndrome is a complex, female endocrine disorder with 
multiple reproductive and endocrine symptoms.  PCOS is the most common 
female endocrine disorder worldwide, possibly affecting up to 15% of the 
reproductive age population. In the United States alone, 5 million women exhibit 
some form of the syndrome. Along with being an incredibly common disorder, it 
is also manifests with many problematic symptoms that can negatively impact the 
quality of life of women diagnosed. A more detailed description is provided in the 
table below.  
 
Table 1. Clinical features of polycystic ovary syndrome 
 Infertility (difficulty or not being able to become pregnant) because of not 
ovulating.  
 Infrequent, absent, and/or irregular menstrual periods 
 Androgen excess 
 Hirsutism — increased hair growth on the face, chest, stomach, back, 
thumbs, or toes 
 Cysts on the ovaries  
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 Acne, oily skin, or dandruff 
 Weight gain or obesity, usually with extra weight around the waist 
 Male-pattern baldness or thinning hair 
 Patches of skin on the neck, arms, breasts, or thighs that are thick and dark 
brown or black 
 Skin tags — excess flaps of skin in the armpits or neck area 
 Pelvic pain 
 Depression and anxiety 
 Sleep apnea — when breathing stops for short periods of time while asleep 
(Womenshealth.gov, 2013)    
  
PCOS is leading cause of infertility in the United States, accounting for 
upwards of 75% of anovulatory infertility. Anovulatory infertility is the inability 
to become pregnant because there is an barrier to typical ovulation. As well as 
being the leading cause of infertility in the United States, there are other 
problematic complications associated with PCOS.  About 50% of women 
diagnosed with PCOS can expect to develop prediabetes or type II diabetes in 
their lifetime, most likely by the age of 40. Moreover, women with PCOS are at a 
4 to 7 times greater risk of developing heart disease and having a stroke. With 
such an array of physiological problematic symptoms, along with the above 
complications, PCOS can have a huge impact on the daily lives of women 
diagnosed. 
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Along with a myriad of physiological symptoms, women with PCOS 
exhibit psychological symptoms. Women with PCOS not only have a higher 
prevalence of depressive symptoms, but also are at a greater risk of developing 
mood regulation disorders and anxiety. Moreover, women with PCOS are often 
found to have a reduced self-reported quality of life than healthy population that 
does not have similar issues.  Some research has been done on these above 
constructs in relation to PCOS; however, more research needs to be conducted on 
other psychological implications of being diagnosed with polycystic ovary 
syndrome. 
 
While there has been some research done on depression, anxiety, and 
quality of life related to PCOS, there has been less research completed on other 
psychosocial experiences in women diagnosed with PCOS, such as how women 
with PCOS experience stress. It is in this framework that I asked my main 
research questions for my project. Firstly, do women with polycystic ovary 
syndrome experience stress differently than a healthy control population? 
Secondly, how does having PCOS affect the health of women diagnosed? I 
expected that women with PCOS would experience stress differently than a 
healthy control population, with greater levels of self-reported perceived stress, as 
well as having greater physiological reactivity to a brief stressor. Also, I expected 
that women with PCOS would report more physical symptoms that they found 
concerning in their daily lives than a healthy control population. 
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To investigate how women with PCOS experienced stress in their lives, I 
conducted a psychology study comparing women diagnosed with polycystic 
ovary syndrome with a healthy control population. I recruited women diagnosed 
with PCOS from the intro psychology research participation pool, as well as from 
the Syracuse University and larger campus communities. Participants were invited 
to the Project Heart Lab space, located at the CNY Medical Building near the 
Syracuse University campus. Participants were asked to complete a brief series of 
questionnaires related to their health and well-being, included a Perceived Stress 
Scale, Symptoms Checklist, and the Center for Epidemiological Studies 
Depression scale. Also, the participants’ basic body measurements taken (height, 
weight, BMI, waist-to-hip ratio), and they were asked to participate in a brief 
interview designed to elicit a short term stress response, the Social Competence 
Interview (SCI). Throughout the study, saliva samples were taken at five time 
points, to later be analyzed for presence of cortisol and amylase. Both cortisol and 
amylase are important during the stress response, and from that data, I aimed to 
evaluate the reactivity of my participants to brief stressor mentioned above, the 
SCI. I analyzed my results using SPSS statistical software. The saliva samples 
collected were sent to Brandeis University to be analyzed. 
Although we did not find a difference in perceived stress, we did find that 
women with PCOS reported more somatic complaints and depressive symptoms 
than healthy controls. Given that PCOS is associated with many problematic 
physical symptoms, i.e. hirsutism, acne, weight gain, and pelvic pain, it is 
expected that women diagnosed with PCOS would have more somatic complaints 
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compared to healthy controls. Further, women with PCOS had a significantly 
higher levels of baseline cortisol than a healthy, control population. 
The findings from this study point to further research on the ties between 
the experiences of stress and the relation to physical and psychological health in 
women diagnosed with polycystic ovary syndrome. This study supported that 
somatic and psychological symptoms associated with PCOS are significantly 
different than a healthy population. As a result, more research needs to be 
conducted on how these symptoms could affect the daily lives of women affected. 
With such a high prevalence among women, affecting over 5 million 
women in the United States alone, PCOS is a leading public health concern. As 
such, it is imperative that there is increased awareness and research in regards to 
the syndrome. Without both of these factors, it is possible that polycystic ovary 
syndrome will not receive the attention that it requires for effective treatments to 
be developed. 
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Rome was not built in a day, and neither will your capstone. This is such a 
wonderful learning experience, and can be even more wonderful if you work at it 
a little bit every day!
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Introduction 
Polycystic Ovary Syndrome 
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that 
affects multiple organ systems within the female body, hallmarked by infertility, 
the possibility of androgen excess, and the possibility of ovulatory dysfunction 
(NIH Report, 2012). Ultimately, PCOS is the leading cause of female infertility 
(Sheehann, 2004), accounting for upwards of 75% of anovulatory infertility 
(Sheehan, 2004). According to the National Institutes of Health report, 5- 15 % of 
reproductive-aged women exhibit some phenotype of the syndrome; this accounts 
for more than 5 million women in the United States alone (NIH Report, 2012). 
Despite the prevalence of this major public health issue (Sanchez, 2014), a long 
history of misdiagnosis and non-diagnosis surrounds the syndrome (Colwell et al, 
2010). Often, independent symptoms are identified without being attributed to a 
chronic health issue (Colwell et al, 2010), making it incredibly difficult for 
women to be diagnosed and treated. 
In a recent NIH workshop, the syndrome was described as a “poorly 
understood condition” for much of the 20th century (NIH Report, 2012). In 1990, 
the NIH held a conference to create a standard for diagnoses and research in 
regards to the syndrome, dually hoping to obtain a more accurate understanding 
of the syndrome and objectives for research (NIH Report, 1990) In a more recent 
workshop, the NIH identified three different classifications systems (described in 
Table 1) that have been used to diagnose women with PCOS over the past 20 
years (NIH Report, 2012). These multiple classifications systems have lead to an 
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inevitable miscommunication between practitioner and patient, ultimately serving 
as an impediment to diagnoses and treatment (NIH Report, 2012). 
Table 2. Differing diagnostic criteria for polycystic ovary syndrome 
NIH Criteria (1990) 
Chronic anovulation, clinical and/or biochemical signs of 
hyperandrogenism (Both criteria needed) 
Rotterdam Criteria (2003) 
Oligo- and/ or anovulation; clinical and/or biochemical signs of 
hyperandrogenism, polycystic ovaries (Two of three criteria needed) 
AE-PCOS Society Criteria 
Clinical and/or biochemical signs of hyperandrogenism; ovarian 
dysfunction (oligo-anovulation and/or polycystic ovarian morphology) 
(Two of three criteria needed)  
 
Polycystic ovary syndrome is associated with a wide variety of physiological and 
psychological symptoms, some relatively minor, others severe. At its simplest 
definition, PCOS is a hormonal imbalance that leads to undesirable symptoms 
such as irregular menstruation, changes in appearance, and infertility (NIH 
Report, 2012). In actuality, the syndrome is complex and misunderstood, and thus 
difficult to treat effectively (Colwell et al, 2010). The complexity of this 
syndrome begins with diagnosis: as there is no one set phenotypic expression of 
the syndrome, the diagnostic criteria must analyze many aspects of a patient’s 
health.  To diagnose PCOS, physicians take an extensive medical history of the 
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patient, order a series of physiological (physical exam, blood tests, lipid profiling, 
and ovarian ultrasound) tests, and take into consideration the symptoms listed 
below. 
Table 2. Clinical features of polycystic ovary syndrome 
 Infertility (difficulty or not being able to become pregnant) because of not 
ovulating.  
 Infrequent, absent, and/or irregular menstrual periods 
 Androgen excess 
 Hirsutism — increased hair growth on the face, chest, stomach, back, 
thumbs, or toes 
 Cysts on the ovaries  
 Acne, oily skin, or dandruff 
 Weight gain or obesity, usually with extra weight around the waist 
 Male-pattern baldness or thinning hair 
 Patches of skin on the neck, arms, breasts, or thighs that are thick and dark 
brown or black 
 Skin tags — excess flaps of skin in the armpits or neck area 
 Pelvic pain 
 Depression and anxiety 
 Sleep apnea — when breathing stops for short periods of time while asleep 
(Womenshealth.gov, 2013)    
 Post diagnoses, the diagnosing practitioner will work on a treatment plan 
for the patient. These treatments generally fall into two categories of intervention, 
one of which being medication. The goal of treatment with medications is to 
attenuate the effects of hormonal abnormalities (excess androgens and estrogens) 
in women with the syndrome. Synthetic hormone treatment, commonly in the 
form of birth control pills, is provided to dually regulate menstrual cycles and 
reduce excessive androgens. Also, for concerns surrounding fertility issues, 
women with PCOS are often provided hormonal treatments that target 
anovulation. One such example is clomiphene, which has been found to have 
some efficacy in treating infertility issues in women with PCOS (Palomba et al, 
2009). 
Further, a practitioner may provide metformin (Glucophage, Glucophage 
Extended Release (XR), to lower insulin levels, increase insulin sensitivity, and 
potentially induce ovulation (Mayo Clinic, 2014). Metformin has been found to 
help those diagnosed manage the overall disorder through increasing insulin 
sensitivity (Nestler, 2002).  In summation, these treatments focus on the 
biochemical abnormalities that are present in women diagnosed with polycystic 
ovary syndrome. 
 Along with medication intervention, another treatment focus is lifestyle 
intervention. Women diagnosed with PCOS are encouraged to eat a healthy diet, 
exercise, and if at all possible, lose weight. Women with PCOS often have 
difficulty losing weight; roughly half of all women diagnosed with PCOS are 
clinically obese (Hoegar, 2001). Maintaining a healthy lifestyle is crucial for 
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women diagnosed with polycystic ovary syndrome, as more than half of women 
diagnosed can expect to develop prediabetes or type II diabetes mellitus prior to 
the age of 40.  
Psychological Implications of PCOS 
As demonstrated by the wide variety of intrusive symptoms above, PCOS 
can exert a strong influence on the lives of those with the syndrome. With such a 
panoply of physiological symptoms, it is not surprising that negative 
psychological consequences can co-occur with negative physiological symptoms.  
PCOS and Depression 
 There has been a high prevalence of mood disorders found in women with 
PCOS, particularly a high prevalence of depressive disorders (Rasgon et al, 2003). 
Both clinical and biochemical symptom correlates have been found in women 
diagnosed with PCOS, with depression being associated to greater insulin 
resistance and higher BMI (Ragson et al, 2003). Thus, there appears to be an 
association between depression and classic PCOS markers (Ragson et al, 2003).  
Stress 
Stress is a common and daily occurrence in modern society. 
Physiologically, stress can be defined as a state in which homeostasis is 
jeopardized by the action of external (environmental) and internal (physiological 
and psychological states) stressors (Bozocvic, Racic, Ivkovic, 2013). In particular 
to psychological state, stress is the experience of a perceived threat, resulting from 
a series of physiological responses and pathways (Seaward, 2012).  
Hypothalamic-Adrenal- Pituitary Axis 
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One of the main systems that regulate the body’s response to stress is the 
hypothalamic-pituitary-adrenal (HPA) axes. An integral part of the HPA axes, the 
hypothalamus, is activated in response to a stressor, producing a “fight or flight” 
response. First proposed by Seyle, this “fight or flight” response is the body’s 
automatic response to stress, preparing the body to either face the stressor or 
remove itself from the situation. This feedback response is first initiated by the 
hypothalamus, which in turn activates the sympathetic nervous system, and finally 
the adrenal-cortical system to eventually release cortisol. 
Cortisol 
The moments following an initial stressor are critical for the body to 
physiologically prepare for an appropriate response to the stressor. The first 
response of the body is by the hypothalamus, which is stimulated to related 
corticotropin-releasing factor by the stressor. In response to this release of 
corticotropin-releasing factor, the anterior gland is stimulated to release 
adrenocorticotropic hormone (ACTH). Finally, the release of ACTH stimulates 
the release of cortisol by the adrenal glands, which enters the bloodstream to 
prepare the body to respond to the stressor. Cortisol, also known as 
hydrocortisone, is a glucocorticoid (steroid hormone), released in response to the 
HPA axes pathway, which begins after perception of a stressor. Cortisol’s primary 
function is to maintain and increase blood sugar through gluconeogenesis, 
suppress the immune system, and aid in metabolism. Simply, cortisol prepares the 
body to respond to a stressor. Therefore, cortisol can be considered a biomarker, 
or indicator, of HPA axis activity and the larger stress response. Cortisol has been 
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demonstrated to be a biomarker of psychosocial stress (Selye et al., 1960; 
Kirschbaum et al., 1995; Eck, 1996; Bozovic, Racic, & Ivkovic, 2013). Typical, 
daily stressful events have been to induce a rapid increase in cortisol secretion 
(Eck et al 1996), further demonstrating cortisol’s utility as a biomarker for 
psychosocial stress. 
Salivary Cortisol 
In a laboratory setting, salivary cortisol is often collected as an indicator of 
psychosocial stress. Through the framework described above, salivary cortisol can 
be utilized as an objective biomarker for psychosocial stress. The present study 
will analyze salivary cortisol samples for a measurement of psychosocial stress. 
Chronic Stress 
While the experience of stress is a daily occurrence, not all types of stress 
are experienced equivalently. Distress, defined as an interpretation that an event 
will have a negative and/or harmful effect on the interpreter (Ridner, 2004), 
becomes increasingly problematic when the experience of stress is chronic. 
Chronic, or prolonged stress, has been shown to have negative implications is 
regards to psychological health and well-being; stressful events have been shown 
to be contributing factors to depression (Hammen, 2005; Kendler et al. 1999) and 
anxiety disorders (Brown et al. 1986).  
Further, chronic stress has been demonstrated to be a contributing factor to 
the development and experience of chronic disease, often accelerating disease 
processes (Nestler et al., 2002). Implications of chronic stress have been 
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documented in regards to many major diseases, including heart disease, immune 
system and hormonal changes such as levels of cortisol (Kirschbaum et al, 1995). 
While the effects of stress on physiological functions have been 
investigated in regards to certain endocrine disorders such as diabetes, there has 
been less focus on the effects of stress on other chronic, endocrine disorders. In 
this paper, I will focus on the effects of stress on women with polycystic ovary 
syndrome. 
Polycystic Ovary Syndrome and Stress 
The need for treatment directed to attenuate any psychological 
implications of the syndrome has become increasingly important, particularly how 
PCOS could affect the experience of stress in women diagnosed. As cited above, 
women with PCOS may experience  
While several researchers have focused on PCOS in a psychosocial 
perspective, including research on depression, anxiety, and quality of life 
(Cipkala-Gaffin et al, 2012); (Ferriday et al, 2007), fewer researchers have 
examined the experiences of stress in women with PCOS, another psychosocial 
experience that may be altered as a result of having PCOS. One striking example 
was a study done by Benson et al., who found that women with PCOS had 
disturbed stress responses, showing an enhanced hypothalamic-pituitary-adrenal 
(HPA) axis and heart rate reactivity in response to a stress interview task (2008). 
After the insertion of a catheter to measure serum cortisol, ACTH, and IL-6 
levels, participants were asked to complete a public speaking task to elicit an 
acute psychosocial stress response. It was supported that women with PCOS had 
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significantly greater increases in HPA-axis mediators (ACTH and cortisol)  than a 
control population (Benson et al., 2008) This seminal work in regards to PCOS 
and psychosocial stress demonstrates the need for a greater understanding of 
stress reactivity in women with polycystic ovary syndrome. 
 
Aims of the Present Study 
Polycystic Ovary Syndrome and Experience of Stress 
 The present study aims to explore how polycystic ovary syndrome could 
affect the health of women with the syndrome, and further, how these effects 
could alter the experiences of stress in their lives.  The study focused on the 
following primary hypotheses. 
  
Hypotheses 
1. Women with polycystic ovary syndrome will report higher levels 
of perceived stress than healthy age-matched controls 
2. Women with polycystic ovary syndrome will report more somatic 
complaints that are problematic to their daily lives. 
3. Women with polycystic ovary syndrome will have a greater 
baseline cortisol and greater cortisol reactivity over time to the 
Social Competence Interview (SCI) compared to controls. 
4. Somatic complaints will be related to psychosocial variables such 
as depression, anxiety, perceived stress across all participants.    
Methods 
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Participants 
 Participants were recruited and screened via advertisements within 
“SONA”, a research participation pool system at Syracuse University, with xx 
being eligible to participate in the study. Also, participants were recruited and 
screened via paper and electronic flyers around the Syracuse University campus 
and surrounding neighborhoods. 78 women, 16 with polycystic ovary syndrome 
and 62 without polycystic ovary syndrome, were included in data analyses. 
Exclusion criteria included several lifestyle factors: currently smoking tobacco 
products, heavy drinking (20 or more drinks per week), age and gender (only 
women between the ages of 18-35 were eligible). Further, diagnoses of one or 
more of the following health concerns would result in ineligibility: atopic 
diseases, allergies requiring regular medications, airway disease (such as asthma), 
autoimmune diseases, cardiovascular problems, gastrointestinal diseases, diseases 
of the urinary tract, and any other hormonal disorders that were not polycystic 
ovary syndrome.  
 The sample was 100 % female, as this was a study concerning women’s 
health; all of the participants were female. The average age of the participants was 
19.05 (SD=2.00) years old. 47% of the participants identified as White, 21% 
identified as Asian, 15% identified as Black, and 13% were other races, more than 
one race, or declined to state their race. The average BMI of the entire sample was 
23.9 kg/m2, (SD=4.9) with the average waist-to-hip ratio (WHR) being .83 (SD=. 
10).   
Procedures 
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Participants were invited to meet a member of the research team outside of 
the CNY Medical Building near Syracuse University, who would guide them to 
the Project Heart Laboratory. The participant was immediately asked if they had 
any caffeine yet that day. If so, the participant was invited to reschedule their 
appointment time, as the presence of caffeine could change the outcome of the 
results. After ensuring the participant did not have any caffeine, the participant 
was guided into a comfortable room, and then provided with a consent form to 
read over on their own.  A research assistant then asked the participant if they had 
any questions on what they read. If there were no questions and the participant 
felt comfortable with the procedures, the participant was invited to sign the 
informed consent, which included information on the Social Competence 
Interview and the methods to collect saliva samples at five repeated measures. 
After signing the informed consent, general body measurements and 
physiological data was collected, including: height (to the nearest quarter inch), 
weight (in kg), and waist-to-hip ratio (WHR). Later, participant BMI was 
calculated from the information collected during the study. Following this, the 
participant was invited to complete the first series of questionnaires. These 
questionnaires included basic demographic information, Perceived Stress Scale  
(PSS) that measures perceived stress (Hewitt, Flett, & Mosher 1992), Symptom 
Checklist (SCL) that collects somatic symptomatic data (Laan et al, 1999), the 
Center for Epidemiologic Studies Depression (CES-D) Scale that measures self-
reported depressive symptoms (Dam & Earlywine, 2011), a scale on body image, 
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and a polycystic ovary syndrome health questionnaire that collected information 
on the participant’s symptomatic experiences with PCOS.  
After 30 minutes of calmly completing questionnaires, the first baseline 
measurement of saliva (labeled “S0”) was taken. Prior to taking the baseline 
measurement, participants were explained the proper procedure for saliva 
collection utilizing salivette tubes. Participants were instructed to roll the salivette 
around their mouth for 60 seconds, trying to reach all parts of their mouth.  
Participants were instructed to refrain from touching the cotton salivette cylinder 
with their hands, along with being instructed to refrain from biting the salivette.  
After 10 minutes of quietly resting, a second baseline measurement (labeled “S1”) 
was taken. At this point, the Social Competence Interview, or SCI, began. A 
Research Assistant that had been trained on the SCI conducted the interview. 
Three more saliva samples were taken throughout the study, one in the middle of 
the Social Competence Interview, or SCI (S2), another at the end of the interview 
(S3), and a last sample ten minutes following the interview (S4). 
 Following the SCI, participants were instructed to relax and complete a 
second set of questionnaires, including two measures on self-reported quality of 
life. The last saliva sample (S4) was taken 10 minutes after the interview was 
complete. At this point, the participant continued to fill out and complete any 
remaining questionnaires in the second questionnaire packet. 
 When the participants finished their final questionnaires, they were 
thanked for their time and effort in completing the study, debriefed by one of the 
Research Assistants, and guided out of the CNY Medical building. The entire 
22 
 
protocol, including entering and exiting the laboratory space, lasted 
approximately 90 minutes. Participants recruited through the SONA research 
participation pool were awarded course credit as compensation. Participants 
recruited through the campus and surrounding communities were awarded $15.00 
as compensation for completing the study. 
The Social Competence Interview 
 The SCI (Ewart at al, 2002) is an 8-12 minute interview designed to elicit 
a short-term stress response. During the interview, participants are asked to 
describe a recent, stressful situation related to a chronic stressor in their lives. 
During the first portion of the interview, participants are asked to recall the 
stressful situation they experienced in as much detail as possible. In the second 
section of the interview, the participant is directed to describe a potential 
solution(s) and coping mechanism(s) to the problem they were previously 
describing. To develop potential solution(s) and coping mechanism(s), the 
participant is then asked to pretend they are the director of a film. This film is 
about character similar to themselves, who is experiencing the same chronic 
stressor and specific stressful experience that the participant had previously 
described.  The participant can direct any ending for their character.  Specifically, 
they are asked to come up with an ideal, realistic ending to the film they 
described, and are later asked to rate their confidence in achieving that particular 
ideal ending.  Participants were asked for their consent to be audio recorded 
during their interview. 
Measures 
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Perceived Stress Scale. The Perceived Stress Scale (PSS) is a 
psychological questionnaire used to measure an individual’s perception of stress 
in their daily lives. Items in the questionnaire are designed to measure how 
unpredictable, uncontrollable, and overloaded respondents find their lives (Cohen 
et al, 1998).  
Symptom Checklist. The Symptom Checklist-90-R (SCL-90-R) is a self-
report questionnaire, designed to evaluate a range of psychological and 
physiological symptoms. In this study, we used an abbreviated measure, only 
including a portion of the questionnaire items.  
Center for Epidemiologic Studies- Depression Scale (CES-D). The CES-D 
is a self-report questionnaire, designed to evaluate depression symptoms. In this 
study, we used this measure to evaluate self-reported symptoms of depression in 
the study sample. 
All measures are presented in Appendix B.  
Data Analysis Plan 
All data analyses were conducted using IBM SPSS Statistics 21 statistical 
software package (IBM, Chicago, IL, USA).  Using descriptive statistics, I 
analyzed the demographics of the study sample.  I examined group differences 
using a series of independent samples t-tests.    
To test Hypothesis 1, whether women with polycystic ovary syndrome 
reported higher levels of perceived stress than healthy age-matched controls, I 
performed an independent samples t-test.  
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To test Hypothesis 2, whether women with polycystic ovary syndrome 
experienced more health concerns, i.e., more somatic complaints and more 
depressive symptoms than healthy age-matched controls, I performed two more 
independent samples t-tests. 
To test Hypothesis 3, whether the Social Competence Interview (SCI) 
elicited changes in cortisol and amylase over time in both women with polycystic 
ovary syndrome and healthy age-matched controls, I performed a repeated 
measures analysis of variance (ANOVA) comparing differences from Time 1 
(baseline sample) to Time 3 (immediately after SCI). 
To test Hypothesis 4, whether perceived somatic complaints were related 
to psychosocial variables such as depression, anxiety, perceived stress, I 
performed a series of Pearson’s correlations.    
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Results 
 
Means and standard deviations for all study variables of interest are 
presented in Table 3 (Appendix A).  Participants ranged in age from 18 to 29 and 
had a mean age of 19.18 (SD= 1.79).  The sample was comprised of 16 of women 
with PCOS and 62 healthy controls.  The two groups differed significantly in 
BMI, t (78) = -3.69, p < .001.  Women with PCOS had a mean BMI of 27.71 
(SD=2.08) while the control group had a mean BMI of 22.99 (SD=. 374). 
 
Hypothesis 1 
 
The hypothesis that women with polycystic ovary syndrome would report 
higher levels of perceived stress than healthy age-matched controls was tested 
with an independent samples t-test. No significant group differences were found, 
PCOS (M = 19.60, SD = 6.60) Control (M = 16.85, SD = 6.28), t (n-1) = -1.50 , p 
> .05.  
 
Hypothesis 2 
  The hypothesis that women with polycystic ovarian syndrome would 
report more somatic complaints and depressive symptoms related to their daily 
lives than healthy age-matched controls was tested with an independent samples t-
test.  Results revealed significant differences between the groups. Women with 
PCOS (M = 31.46, SD = 21.48) reported significantly higher levels of perceived 
somatic complaints than healthy controls (M = 21.16, SD = 11.59),  
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t(71) = 2.44, p = .02.  Women with PCOS (M=43.0, SD = 11.2) also reported 
more symptoms of depression than healthy controls (M=36.9, SD=8.5), t(64) = 
2.05, p=.05 
 
Hypothesis 3 
The hypothesis that women with polycystic ovary syndrome would have 
greater physiological reactivity as measured by cortisol compared to controls was 
tested with an independent samples t-test. Results revealed a significant difference 
between the groups, but in the opposite direction than hypothesized. Women with 
PCOS had a greater decline in cortisol (M= -1.67, SD= 2.93) than healthy 
controls (M = -.31, SD =1.99), t(65) = 2.11, p= .04. 
                                                                                                                                    
                  Further analysis via a repeated measures ANOVA showed that, for all 
participants, the difference in change in cortisol level between the first baseline 
time point (M = 9.89, SD = 4.94) and the third time point, immediately after the 
SCI, (M = 8.39, SD = 4.31) was statistically significant, F(1,66) = 18.564, p < 
.001. There was a significant decrement in cortisol from Time 1 to Time 3 across 
all participants.  
Means and standard deviations for cortisol samples for each time, by 
group, is presented in Table 4 (Appendix A).   
 
Hypothesis 4 
The hypothesis that perceived somatic complaints were related to 
psychosocial variables such as depression, anxiety, perceived stress was tested 
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with Pearson Correlations were calculated.    There was a moderate, statistically 
significant, positive correlation between somatic complaints and depression; r 
(63) = .53,  p<0.01.               
There was a moderate, statistically significant, positive correlation 
between somatic complaints and trait anxiety; r(40) = .49,  p<0.01.               
There was a moderate, statistically significant, positive correlation 
between somatic complaints and reported perceived stress; r (63) = .55,  p<0.01. 
There was a moderate, statistically significant, positive correlation 
between somatic complaints and BMI; r (70) = .33,  p<0.01.               
 
Discussion 
    The purpose of this study was to explore how polycystic ovary syndrome 
affects the health of the women diagnosed, and how these effects could alter the 
experiences of stress in their lives. We found that women with PCOS did not 
report higher levels of perceived stress than healthy controls (Hypothesis 1). 
 Given that this was a college sample, it is possible that all participants 
experienced similar levels of stress in their daily lives, independent of any 
medical condition. 
 
Although we did not find a difference in perceived stress, we did find that 
women with PCOS reported more somatic complaints and depressive symptoms 
than healthy controls. Given that PCOS is associated with many problematic 
physical symptoms, i.e. hirsutism, acne, weight gain, and pelvic pain, it is 
expected that women diagnosed with PCOS would have more somatic complaints 
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compared to healthy controls. Along with physical symptoms, women with 
polycystic ovary syndrome have been found to have high incidences of depressive 
symptoms, ranging from 28 to 64 % of women diagnosed (Bazarganipour et al, 
2013 ; Bhattacharya, 2010; Deeks, Gibson-Helm, Teede, 2010). My results 
concurred with the previous literature, finding that women diagnosed with PCOS 
reported more depressive symptoms than healthy controls. Similarly to somatic 
complaints, the physical symptoms associated with PCOS may contribute to 
increased depressive symptoms. In line with this, we found a moderate positive 
correlation between somatic complaints and depressive symptoms across all 
participants. As reported somatic complaints increased, so did the reported 
depressive symptoms for all participants.    
 
It is difficult to interpret the results of Hypothesis 3, that women with 
PCOS would experience greater physiological reactivity to the SCI, because an 
unexpected decline in salivary cortisol was observed for all participants 
throughout the study, suggesting there was not an activation of the HPA axes due 
to the SCI. Possibly, the most physiologically stressful part of the study was 
meeting an unfamiliar Research Assistant to be brought to the laboratory.  At the 
end of the study, many participants reported feeling that the interview was 
therapeutic, rather than stressful.  
 
Across all participants, I found that there were moderate to strong 
correlations between somatic complaints and reported depressive symptoms, 
anxiety, and perceived stress. The results suggest that in my study sample, 
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distressing physical symptoms may contribute to higher levels of psychiatric 
symptoms. 
 
Significance of Study 
 This study is one of the first to examine the implications of psychosocial 
stressors in a specific population, women diagnosed with polycystic ovary 
syndrome. Currently, this population is underserved in terms of psychological and 
psychosocial research; this study serves to contribute to the deficit in knowledge 
within the field.   
This study is the first to examine indicators of physical health such as BMI 
and somatic complaints, and indicators of mental health such as depressive 
symptoms, anxiety, and perceived stress in college-age women diagnosed with 
polycystic ovary syndrome. The study was also the first to examine changes in 
cortisol in response to a psychosocial stressor, the Social Competence Interview, 
in this population.       
Strengths of this study include the fact that participants were screened for 
existing medical conditions; participants with confounding medical conditions 
(e.g., psychiatric illnesses such as Major Depressive Disorder, ADHD, 
Generalized Anxiety Disorder, etc.) were not included in the study. Further, the 
control population was large (N= 62) compared to the experimental group 
(N=16). 
 
Limitations 
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Although this study had many areas of strength, there were still some 
limitations.  One key limitation is the sample size in women diagnosed with 
polycystic ovary syndrome was small relative to the control population. 
Considering this, it is difficult to draw conclusions that could generalize to a 
broader population of women with polycystic ovary syndrome. Another key 
limitation is that the laboratory stressor, the SCI, may not have induced an HPA 
axes response, making it difficult to examine how this population responded to a 
stressor. Lastly, my study mostly contained a population of relatively young, 
college-educated women. Results may not be able to generalizable to a larger 
population with more diverse backgrounds.  
 
Future Directions 
The findings from this study point to further research on the ties between 
the experiences of stress and the relation to the physical and psychological health 
in women diagnosed with polycystic ovary syndrome. This study supported that 
somatic and psychological symptoms associated with PCOS are significantly 
different than a healthy population. As a result, more research needs to be 
conducted on how these symptoms could affect the daily lives of women affected. 
Like for many who face disorders with difficult and often problematic 
symptoms, the necessity of medical, psychological, and social support is 
paramount. Thus, more research needs to be done on the potential benefits of 
psychological support in women with polycystic ovary syndrome. 
Finally, it has only been in recent years that PCOS has garnered attention 
and credibility, both in the medical field and society. As a result, both women 
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diagnosed with polycystic ovary syndrome and those hoping to raise awareness 
for the syndrome may have difficulty finding the language to discuss the 
syndrome. Therefore, an interesting line of research may include not only more 
investigation on the psychological impacts of the disorder, but the best methods to 
increase awareness and communication between health care practitioners, those 
affected, and their larger communities.  
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Appendix A 
 
 
Table 3 
Means, Standard Deviations, and Pearson Correlations for Selected Study 
Variables 
  Mean (SD) r 
    1. 2. 3. 4.  
1.      Symptoms 
Checklist* 
PCOS, 31.46 (21.48); 
Control, 21.17 (11.60) 
1        
2.      CES-D* PCOS, 43.00(11.20); 
Control, 36.90(8.54) 
.528** 1      
3.      Self-report 
Trait Anxiety 
PCOS, xx(xx); Control, 
43.97(11.29) 
.486** .740** 1    
4.      Percieved 
Stress Scale 
PCOS, 19.64 (7.58); 
Control,  17.23(7.58) 
.553** .710** .827** 1  
5.      BMI* PCOS, 27.71 (8.30); 
Control, 22.99(2.99) 
.331** .052 -.062 .006  
Note.  ** indicates correlations significant at p < .01. 
* indicates significant difference between means and standard deviations of 
groups. 
xx indicated data not included in analysis. 
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Table 4 
Means and Standard Deviations for Cortisol Samples by Group 
  Cortisol (nmol/L) 
  PCOS Controls 
Time 1 10.98 (6.44) 8.8 (4.4) 
Time 2 10.31(7.04) 8.1 (3.2) 
Time 3  9.20(6.50) 7.5 (3.4) 
Time 4  8.64(5.99) 7.4 (3.1) 
Time 5  7.34(4.84) 6.8 (3.5) 
Note. PCOS, N=16, Control N=51  
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PSS 
 
 
The questions in this scale ask you about your feelings and thoughts during the last 
month. In each case, please indicate with a check how often you felt or thought a 
certain way. 
 
 Never Almost 
never 
Sometime
s 
Fairly 
often 
Very often 
1. In the last month, how 
often have you been upset 
because of something that 
happened unexpectedly? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
2. In the last month, how 
often have you felt that you 
were unable to control the 
important things in your 
life? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
3. In the last month, how 
often have you felt nervous 
and "stressed"? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
4. In the last month, how 
often have you felt confident 
about your ability to handle 
your personal problems? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
5. In the last month, how 
often have you felt that 
things were going your way? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
6. In the last month, how 
often have you found that 
you could not cope with all 
the things that you had to 
do? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
7. In the last month, how 
often have you been able to 
control irritations in your 
life? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
8. In the last month, how 
often have you felt that you 
were on top of things? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
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9. In the last month, how 
often have you been angered 
because of things that were 
outside of your control? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
10. In the last month, how often 
have you felt difficulties were 
piling up so high that you could 
not overcome them? 
 
0 
 
 
 
1 
 
2 
 
3 
 
4 
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CESD 
Below is a list of the ways you might have felt or behaved. Please tell me how 
often you have felt this way during the past week. 
1 = Rarely or None of the Time (Less than 1 Day) 
2 = Some or a Little of the Time (1-2 Days) 
3 = Occasionally or a Moderate Amount of Time (3-4 Days) 
4 = Most or All of the Time (5-7 Days) 
During the past week: 
R
ar
el
y 
or
 N
on
e 
of
 th
e 
Ti
m
e 
(L
es
s 
th
an
 1
 D
ay
) 
So
m
e 
or
 a
 L
it
tle
 o
f t
he
 T
im
e 
(1
-2
 D
ay
s)
 
O
cc
as
io
na
lly
 o
r 
a 
M
od
er
at
e 
A
m
ou
nt
 o
f T
im
e 
(3
-4
 D
ay
s)
 
 M
os
t o
r 
A
ll 
of
 th
e 
Ti
m
e 
(5
-7
 D
ay
s)
 
1. I was bothered by things that 
usually don’t bother me. 1 2 3 4 
2. I did not feel like eating; my appetite 
was poor. 1 2 3 4 
3. I felt that I could not shake off the 
blues even with help from my family 
or friends. 
1 2 3 4 
4. I felt that I was just as good as other 
people. 1 2 3 4 
5. I had trouble keeping my mind on 
what I was doing. 1 2 3 4 
6. I felt depressed. 1 2 3 4 
7. I felt that everything I did was an 
effort. 1 2 3 4 
8. I felt hopeful about the future. 1 2 3 4 
9. I thought my life had been a failure. 1 2 3 4 
10. I felt fearful. 1 2 3 4 
11. My sleep was restless. 1 2 3 4 
12. I was happy. 1 2 3 4 
13. I talked less than usual. 1 2 3 4 
14. I felt lonely. 1 2 3 4 
15. People were unfriendly. 1 2 3 4 
16. I enjoyed life. 1 2 3 4 
17. I had crying spells. 1 2 3 4 
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18. I felt sad. 1 2 3 4 
19. I felt that people dislike me. 1 2 3 4 
20. I could not get “going”. 1 2 3 4 
 
SCL 
 
Below is a list of symptoms that young adults sometimes have.  Circle a number 
telling how much you were bothered by each symptom during the past two 
weeks. 
 
In the last two weeks, how much were you bothered by each symptom? 
 
 
 Never Almost 
never 
Sometime
s 
Fairly 
often 
Very often 
 
1.   Headaches  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
2.  Faintness or dizziness 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
3.   Pain in your heart or 
chest   
 
0 
 
1 
 
2 
 
3 
 
4 
 
4.   Feeling low in energy or 
slowed down  
 
0 
 
1 
 
2 
 
3 
 
4 
 
5.   Pains in your lower back
  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
6.   Sore muscles  
 
 
0 
 
1 
 
2 
 
3 
 
4 
7.  Trouble caution your 
breath (when you're not 
exercising) 
 
0 
 
1 
 
2 
 
3 
 
4 
 
8.   Hot or cold spells 
(suddenly feeling hot
 or cold) 
 
0 
 
1 
 
2 
 
3 
 
4 
 
9.   Numbness or tingling in 
parts of your body 
 
0 
 
1 
 
2 
 
3 
 
4 
 
10.  A lump in your throat  
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
11.  Weakness (feeling weak) 
in parts of your body 
 
0 
 
1 
 
2 
 
3 
 
4 
 
12.  Heavy feelings in your 
arms or legs 
 
0 
 
1 
 
2 
 
3 
 
4 
 
13.  Nausea or upset 
stomach 
 
0 
 
1 
 
2 
 
3 
 
4 
 
14.  Constipation 
 
0 
 
1 
 
2 
 
3 
 
4 
 
15.  Loose (runny) bowel 
movements or diarrhea  
 
0 
 
1 
 
2 
 
3 
 
4 
 
16.  Pain in your stomach or 
abdomen 
 
0 
 
1 
 
2 
 
3 
 
4 
 
17.  Your heart beating too 
fast 
 
0 
 
1 
 
2 
 
3 
 
4 
 
18.  Difficulty swallowing 
 
0 
 
1 
 
2 
 
3 
 
4 
 
19.  Losing your voice  
 
0 
 
1 
 
2 
 
3 
 
4 
 
20.  Deafness 
 
0 
 
1 
 
2 
 
3 
 
4 
 
21.  Double vision 
 
0 
 
1 
 
2 
 
3 
 
4 
 
22.  Blurred vision  
 
0 
 
1 
 
2 
 
3 
 
4 
 
23.  Blindness  
 
0 
 
1 
 
2 
 
3 
 
4 
 
24.  Fainting or passing out 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
25.  Memory loss or amnesia 
 
0 
 
1 
 
2 
 
3 
 
4 
 
26.  Seizures or convulsions 
 
0 
 
1 
 
2 
 
3 
 
4 
 
27.  Trouble walking 
 
0 
 
1 
 
2 
 
3 
 
4 
 
28.  Paralysis or muscle 
weakness   
 
0 
 
1 
 
2 
 
3 
 
4 
 
29.  Difficulty urinating 
0 1 2 3 4 
 
30.  Vomiting 
 
0 
 
1 
 
2 
 
3 
 
4 
 
31.  Feeling bloated or gassy 
 
0 
 
1 
 
2 
 
3 
 
4 
 
32.  Food making you sick 
 
0 
 
1 
 
2 
 
3 
 
4 
 
33.  Pain in your knees, 
elbows or other joints 
 
0 
 
1 
 
2 
 
3 
 
4 
 
34.  Pain in your arms or 
legs  
 
0 
 
1 
 
2 
 
3 
 
4 
 
35.  Pain when you urinate 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
 
 
.   
 
 
 
